Associations of <i>TIMP-3</i> Genetic Polymorphisms with <i>EGFR</i> Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients

Associations of <i>TIMP-3</i> Genetic Polymorphisms with <i>EGFR</i> Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients

Lung adenocarcinoma (LADC) is a major subtype of lung cancer, particularly among populations of East Asia. The epidermal growth factor receptor (EGFR) is the most frequently mutated oncogene promoting LADC progression and can serve as a therapeutic target in LADC. The tissue inhibitor of metalloprot...

Full description

Bibliographic Details
Main Authors:	Jer-Hwa Chang, Tsung-Ching Lai, Po-Jen Yang, Pei-Chun Shih, Yi-Chieh Yang, Kai-Ling Lee, Tu-Chen Liu, Thomas Chang-Yao Tsao, Shun-Fa Yang, Ming-Hsien Chien
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	International Journal of Molecular Sciences
Subjects:	tissue inhibitor of metalloproteinases-3 polymorphism epidermal growth factor receptor mutation lung adenocarcinoma
Online Access:	https://www.mdpi.com/1422-0067/21/21/8023

Similar Items

Potential Impacts of <i>Interleukin-17A</i> Promoter Polymorphisms on the <i>EGFR</i> Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan
by: Kai-Ling Lee, et al.
Published: (2021-03-01)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of <i>EGFR</i>-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable <i>EGFR</i> Mutations in Cerebrospinal Fluid
by: Pei-Ya Liao, et al.
Published: (2022-06-01)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of <i>EGFR</i>-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
by: Anastasios Gkountakos, et al.
Published: (2022-01-01)

Association between <i>EGFR</i> Gene Mutation and Antioxidant Gene Polymorphism of Non-Small-Cell Lung Cancer
by: Ching-Hsiung Lin, et al.
Published: (2020-09-01)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
by: Lu Bai, et al.
Published: (2023-01-01)

The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer
by: Maciej Szmitkowski, et al.
Published: (2012-04-01)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
by: Seo Yun Kim, M.D., et al.
Published: (2019-01-01)

Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
by: Sheng‐Yuan Wang, et al.
Published: (2022-01-01)

MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma
by: Zhang W, et al.
Published: (2019-12-01)

Immunohistochemical expression analysis of MMP-1, TIMP-2 and p53 in Barrett’s esophagus, dysplasia and esophageal adenocarcinoma
by: Alejandro García-Varona, et al.
Published: (2021-05-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Correlation of <i>TIMP1-MMP2/MMP9</i> Gene Expression Axis Changes with Treatment Efficacy and Survival of NSCLC Patients
by: Jacek Pietrzak, et al.
Published: (2023-06-01)

<i>Mahonia aquifolium</i> Extracts Promote Doxorubicin Effects against Lung Adenocarcinoma Cells In Vitro
by: Ana Damjanović, et al.
Published: (2020-11-01)

Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma
by: Li‐Han Hsu, et al.
Published: (2019-04-01)

Expression of Tissue Inhibitors of Metalloproteinases (TIMP-1, TIMP-2, TIMP-3, TIMP-4) in Blood Serum of Patients with Keratoconus
by: Marta Nowak-Wąs, et al.
Published: (2024-02-01)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
by: Sheng-Kai Liang, et al.
Published: (2021-01-01)

Circulating <i>EGFR</i> Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
by: Shih-Hong Li, et al.
Published: (2022-09-01)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
by: Ki-Chang Lee, et al.
Published: (2021-03-01)

Is the expression of matrix metalloproteinases (MMP-2, -9) and tissue inhibitors of metalloproteinases (TIMP-1, -2, and -3) associated with angiogenesis and clinicopathological features for breast cancer?
by: Suada Kuskunović-Vlahovljak, et al.
Published: (2017-12-01)

Topical Application of <i>Aronia melanocarpa</i> Extract Rich in Chlorogenic Acid and Rutin Reduces UVB-Induced Skin Damage via Attenuating Collagen Disruption in Mice
by: Young Her, et al.
Published: (2020-10-01)

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
by: Jeonghyo Lee, et al.
Published: (2022-09-01)

CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses
by: Dongdong Mei, et al.
Published: (2018-12-01)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with <i>EGFR</i>-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
by: Ming-Ju Tsai, et al.
Published: (2023-03-01)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
by: Wensheng Zhou, et al.
Published: (2022-03-01)

Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients
by: Ya-Yen Yu, et al.
Published: (2020-04-01)

Urinary Metalloproteinases-9 and -2 and Their Inhibitors TIMP-1 and TIMP-2 are Markers of Early and Long-Term Graft Function After Renal Transplantation
by: Ewa Kwiatkowska, et al.
Published: (2016-05-01)

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas
by: Xiaoyu Han, et al.
Published: (2020-07-01)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
by: Chia-Yu Kuo, et al.
Published: (2022-12-01)

Sustaining the Activation of EGFR Signal by Inflammatory Cytokine IL17A Prompts Cell Proliferation and EGFR-TKI Resistance in Lung Cancer
by: Kai-Ling Lee, et al.
Published: (2023-06-01)

MMPs and TIMPs expression in facial tissue of children with cleft lip and palate
by: Liene Smane-Filipova, et al.
Published: (2016-12-01)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016-07-01)

Relationships of MMP-9 and TIMP-1 proteins with chronic obstructive pulmonary disease risk: A systematic review and meta-analysis
by: Yangxue Li, et al.
Published: (2016-01-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

The serum levels of circulating matrix metalloproteinase MMP-9, MMP-2/TIMP-2 complex and TIMP-1 do not change significantly during normal pregnancy: a pilot study
by: Ritva Nissi, et al.
Published: (2021-01-01)

Differential Expression of EGFR-1, MMP-3, and MMP-9 in Spontaneous Abortions, Induced Abortions, and Tubal Pregnancies
by: Mahi BALCI, et al.
Published: (2019-01-01)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
by: Hyungjin Kim, et al.
Published: (2019-07-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less <i>KRAS</i> and More <i>EGFR</i> Mutations Compared to Advanced Adenocarcinomas
by: Jennie Petterson, et al.
Published: (2024-03-01)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma
by: Po-Hsin Lee, et al.
Published: (2022-07-01)